Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2020

  1. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2017

  1. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356

  2. Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (Clin Transl Oncol, 10.1007/s12094-016-1535-8)

    Clinical and Translational Oncology

  3. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300

2013

  1. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: A prospective, observational study

    Supportive Care in Cancer, Vol. 21, Núm. 11, pp. 3039-3049

2011

  1. Psychometric properties of the Perform Questionnaire: A brief scale for assessing patient perceptions of fatigue in cancer

    Supportive Care in Cancer, Vol. 19, Núm. 5, pp. 657-666

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

2009

  1. Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: Item generation and item reduction

    Value in Health, Vol. 12, Núm. 1, pp. 130-138

  2. Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study

    Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314

  3. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2007

  1. The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials

    Clinical Breast Cancer, Vol. 7, Núm. 10, pp. 764-774